Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
作者信息
Lee Han Ah, Seo Yeon Seok, Kim Seung Up
机构信息
Department of Internal Medicine, Institute of Gastroenterology, Korea University College of Medicine, Seoul Korea.
Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine and, Yonsei Liver Center, Severance Hospital, Seoul, Korea.
出版信息
Gastroenterology. 2020 Jun;158(8):2310-2311. doi: 10.1053/j.gastro.2019.11.314. Epub 2020 Mar 19.
PMID:32201178
Abstract
摘要
相似文献
1
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.慢性乙型肝炎患者中，替诺福韦与恩替卡韦相比引发肝细胞癌的风险
Gastroenterology. 2020 Jun;158(8):2310-2311. doi: 10.1053/j.gastro.2019.11.314. Epub 2020 Mar 19.
2
Is Tenofovir Associated with a Lower Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Compared With Entecavir?与恩替卡韦相比，替诺福韦在慢性乙型肝炎患者中是否与较低的肝细胞癌风险相关？
Gastroenterology. 2020 Jun;158(8):2311-2312. doi: 10.1053/j.gastro.2020.02.062. Epub 2020 Mar 19.
3
Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply.社论：接受替诺福韦或恩替卡韦治疗的慢性乙型肝炎患者发生肝细胞癌的风险相似——来自欧洲的新线索。作者回复
Aliment Pharmacol Ther. 2021 Mar;53(5):659. doi: 10.1111/apt.16251.
4
Editorial: similar risk of hepatocellar carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe.社论：接受替诺福韦或恩替卡韦治疗的慢性乙型肝炎患者患肝细胞癌的风险相似——来自欧洲的新线索
Aliment Pharmacol Ther. 2021 Mar;53(5):657-658. doi: 10.1111/apt.16238.
5
Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B".回复：“在患有慢性乙型肝炎的白种人患者中，长期使用恩替卡韦或替诺福韦治疗期间肝细胞癌的风险相似”
J Hepatol. 2021 Jan;74(1):246-247. doi: 10.1016/j.jhep.2020.09.005. Epub 2020 Sep 26.
6
Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.恩替卡韦或替诺福韦在西班牙慢性乙型肝炎患者队列中的有效性和安全性：验证Page-B评分预测肝细胞癌的作用
Dig Dis Sci. 2017 Mar;62(3):784-793. doi: 10.1007/s10620-017-4448-7. Epub 2017 Jan 11.
7
Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B.慢性乙型肝炎患者中，使用替诺福韦与恩替卡韦治疗后患肝细胞癌的风险
Lancet Gastroenterol Hepatol. 2021 Feb;6(2):87. doi: 10.1016/S2468-1253(20)30372-1.
8
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.在患有慢性乙型肝炎的白种人患者中，长期使用恩替卡韦或替诺福韦治疗期间肝细胞癌风险相似。
J Hepatol. 2021 Jan;74(1):245-246. doi: 10.1016/j.jhep.2020.07.038. Epub 2020 Sep 30.
9
A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.韩国一项恩替卡韦与替诺福韦治疗初治慢性乙型肝炎预后的多中心研究。
J Hepatol. 2019 Sep;71(3):456-464. doi: 10.1016/j.jhep.2019.03.028. Epub 2019 Apr 6.
10
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma.恩替卡韦与替诺福韦治疗慢性乙型肝炎患者：预防肝细胞癌的敌友。
Clin Mol Hepatol. 2021 Jul;27(3):402-412. doi: 10.3350/cmh.2021.0179. Epub 2021 Jun 23.
引用本文的文献
1
Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma.自然杀伤细胞活性是肝癌根治性治疗后复发风险的一个危险因素。
BMC Gastroenterol. 2021 Jun 12;21(1):258. doi: 10.1186/s12876-021-01833-2.
Zotero 插件